Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Time to Revisit Using 10-Year Risk to Guide Statin Therapy.

Publication ,  Journal Article
Navar, AM; Fonarow, GC; Pencina, MJ
Published in: JAMA Cardiol
August 1, 2022

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JAMA Cardiol

DOI

EISSN

2380-6591

Publication Date

August 1, 2022

Volume

7

Issue

8

Start / End Page

785 / 786

Location

United States

Related Subject Headings

  • Primary Prevention
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • Cardiovascular Diseases
  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Navar, A. M., Fonarow, G. C., & Pencina, M. J. (2022). Time to Revisit Using 10-Year Risk to Guide Statin Therapy. JAMA Cardiol, 7(8), 785–786. https://doi.org/10.1001/jamacardio.2022.1883
Navar, Ann Marie, Gregg C. Fonarow, and Michael J. Pencina. “Time to Revisit Using 10-Year Risk to Guide Statin Therapy.JAMA Cardiol 7, no. 8 (August 1, 2022): 785–86. https://doi.org/10.1001/jamacardio.2022.1883.
Navar AM, Fonarow GC, Pencina MJ. Time to Revisit Using 10-Year Risk to Guide Statin Therapy. JAMA Cardiol. 2022 Aug 1;7(8):785–6.
Navar, Ann Marie, et al. “Time to Revisit Using 10-Year Risk to Guide Statin Therapy.JAMA Cardiol, vol. 7, no. 8, Aug. 2022, pp. 785–86. Pubmed, doi:10.1001/jamacardio.2022.1883.
Navar AM, Fonarow GC, Pencina MJ. Time to Revisit Using 10-Year Risk to Guide Statin Therapy. JAMA Cardiol. 2022 Aug 1;7(8):785–786.

Published In

JAMA Cardiol

DOI

EISSN

2380-6591

Publication Date

August 1, 2022

Volume

7

Issue

8

Start / End Page

785 / 786

Location

United States

Related Subject Headings

  • Primary Prevention
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • Cardiovascular Diseases
  • 3201 Cardiovascular medicine and haematology